DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Trasylol (Aprotinin) - Published Studies

 
 



Trasylol Related Published Studies

Well-designed clinical trials related to Trasylol (Aprotinin)

Comparative evaluation of the effects of tranexamic acid and low-dose aprotinin on post-valvular heart surgery bleeding and allogenic transfusion. [2012]

Impact of aprotinin and renal function on mortality: a retrospective single center analysis. [2011.08.30]

A Randomized Trial of Aprotinin-Free Fibrin Sealant Versus Absorbable Hemostat. [2011.08.25]

Aprotinin and classic wound drainage are unnecessary in total hip replacement - a prospective randomized trial. [2011.01.27]

A randomized, placebo-controlled trial of aprotinin to reduce primary graft dysfunction following lung transplantation. [2011.01]

A randomized, placebo-controlled trial of aprotinin to reduce primary graft dysfunction following lung transplantation. [2010.08.19]

Low postoperative dose of aprotinin reduces bleeding and is safe in patients receiving clopidogrel before coronary artery bypass surgery. A prospective randomized study. [2010.04]

High-dose aprotinin does not affect troponin I, N-Terminal pro-B-type natriuretic peptid and renal function in children submitted to surgical correction with extracorporeal circulation. [2009.12]

A randomized clinical trial investigating the relationship between aprotinin and hypercoagulability in off-pump coronary surgery. [2009.11]

Does aprotinin preserve platelets in children with acyanogenic congenital heart disease undergone surgery with cardiopulmonary bypass? [2009.09]

Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial. [2009.08]

The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: a randomized, double-blind, placebo-controlled, noninferiority trial. [2009.07]

A possible association between aprotinin and improved survival after radical surgery for mesothelioma. [2009.02.15]

A possible association between aprotinin and improved survival after radical surgery for mesothelioma. [2009.01.06]

Aprotinin for patients exposed to clopidogrel before off-pump coronary bypass. [2008.12]

Efficacy of a high-dose aprotinin regimen for reducing transfusion requirements and inflammatory responses in adult cardiac surgery. [2008.09]

A randomized, controlled trial of aprotinin in neonates undergoing open-heart surgery. [2008.09]

Is aprotinin safe to use in a cohort at increased risk for thrombotic events: results from a randomized, prospective trial in off-pump coronary artery bypass. [2008.09]

The efficacy of aprotinin in arterial switch operations in infants. [2008.09]

A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. [2008.05.29]

Benefits and risks of aprotinin use during cardiac surgery. [2008.01]

Aprotinin use in cardiac surgery patients at low risk for requiring blood transfusion. [2007.07]

Cardioprotective effect of aprotinin on myocardial ischemia/reperfusion injury during cardiopulmonary bypass. [2006.11]

Effects of minimal dose aprotinin on blood loss and fibrinolytic system-complement activation in coronary artery bypass grafting surgery. [2006.07]

Effects of half-dose aprotinin in off-pump coronary artery bypass grafting. [2006.06]

Aprotinin Does Not Diminish Blood Loss in Elective Operations for Infrarenal Abdominal Aneurysms: A Randomized Double-Blind Controlled Trial. [2006.05.24]

Aprotinin does not diminish blood loss in elective operations for infrarenal abdominal aneurysms: a randomized double-blind controlled trial. [2006.05]

[Effect of aprotinin on selected parameters of coagulation and drainage blood loss after cardiac operations in patients without coagulation disorders] [2006.05]

Comparison of the effects of aprotinin and tranexamic acid on blood loss and red blood cell transfusion requirements during the late stages of liver transplantation. [2006.04]

Aprotinin in the management of Achilles tendinopathy: a randomised controlled trial. [2006.03]

Does aprotinin reduce blood loss in total hip arthroplasty? [2006.01]

Aprotinin shows both hemostatic and antithrombotic effects during off-pump coronary artery bypass grafting. [2006.01]

The effects of aprotinin and tranexamic acid on thrombin generation and fibrinolytic response after cardiac surgery. [2005.10]

Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo). [2005.10]

Kidney-specific proteins in patients receiving aprotinin at high- and low-dose regimens during coronary artery bypass graft with cardiopulmonary bypass. [2005.09]

Aprotinin decreases postoperative bleeding and number of transfusions in patients on clopidogrel undergoing coronary artery bypass graft surgery: a double-blind, placebo-controlled, randomized clinical trial. [2005.08.30]

Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty--a prospective randomized double-blind placebo-controlled study. [2005.07]

Mini-dose pump-prime aprotinin inhibited enhanced fibrinolytic activity and reduced blood loss and transfusion requirements after coronary artery bypass surgery. [2005.06]

Combination of acute preoperative plateletpheresis, cell salvage, and aprotinin minimizes blood loss and requirement during cardiac surgery. [2005.03]

[Effects of topical applications of aprotinin and tranexamic acid on blood loss after open heart surgery] [2005.03]

Which may be effective to reduce blood loss after cardiac operations in cyanotic children: tranexamic acid, aprotinin or a combination? [2005.01]

Randomized controlled trials of aprotinin in cardiac surgery: could clinical equipoise have stopped the bleeding? [2005]

Aprotinin decreases the incidence of cognitive deficit following CABG and cardiopulmonary bypass: a pilot randomized controlled study. [2004.12]

Clinical inhibition of the seven-transmembrane thrombin receptor (PAR1) by intravenous aprotinin during cardiothoracic surgery. [2004.10.26]

[Dynamics of thrombin-antithrombin-III complex (TAT-III) and prothrombin fragments F1 + 2 during labour with and without aprotinin administration] [2004.06]

Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury. [2004.03]

The importance of aprotinin and pentoxifylline in preventing leukocyte sequestration and lung injury caused by protamine at the end of cardiopulmonary bypass surgery. [2004.02]

The prophylactic use of tranexamic acid and aprotinin in orthotopic liver transplantation: a comparative study. [2004.02]

Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass. [2004.02]

Cost analysis of aprotinin for coronary artery bypass patients: analysis of the randomized trials. [2004.02]

Heparin-level-based anticoagulation management during cardiopulmonary bypass: a pilot investigation on the effects of a half-dose aprotinin protocol on postoperative blood loss and hemostatic activation and inflammatory response. [2004.02]

Effects of epsilon-aminocaproic acid and aprotinin on leukocyte-platelet adhesion in patients undergoing cardiac surgery. [2004.02]

Impact of tranexamic acid vs. aprotinin on blood loss and transfusion requirements after cardiopulmonary bypass: a prospective, randomised, double-blind trial. [2004.01]

Leukocyte filtration and aprotinin: synergistic anti-inflammatory protection. [2004]

[Aprotinin reduces myocardial injury in the off-pump coronary artery bypass grafting] [2003.12.10]

Aprotinin reduces blood loss during spinal surgery in children. [2003.11.01]

Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: a randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. [2003.11]

Platelet activation and the protective effect of aprotinin in hepatolithiasis patients. [2003.11]

A randomized trial of aprotinin (Trasylol) on blood loss, blood product requirement, and myocardial injury in total arterial grafting. [2003.10]

Efficacy of aprotinin in reducing blood loss in spinal fusion for idiopathic scoliosis. [2003.09]

Efficacy of aprotinin in children undergoing craniofacial surgery. [2003.08]

Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin. [2003.08]

Dose-dependent effect of aprotinin on aggravated pro-inflammatory cytokines in patients with pulmonary hypertension following cardiopulmonary bypass. [2003.07]

The efficacy and safety of aprotinin for hemostasis during intracranial surgery. [2003.06]

[Changes of fibrinolysis during labour with and without aprotinin application] [2003.05]

Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery: a prospective, double-blind, randomised and placebo-controlled study. [2003.03]

Aprotinin reduces vasoactive medication use during adult liver transplantation. [2003.02]

Fibrinolytic activity and bleeding after cardiac surgery with cardiopulmonary bypass and low-dose aprotinin therapy. [2003.02]

High-dose aprotinin reduces activation of hemostasis, allogeneic blood requirement, and duration of postoperative ventilation in pediatric cardiac surgery. [2003.02]

Does aprotinin influence the inflammatory response to cardiopulmonary bypass in patients? [2003.01]

Soluble adhesion molecules in coronary surgery and cardiopulmonary bypass with pump prime aprotinin. [2002.12]

Aprotinin reduces blood loss in off-pump coronary artery bypass (OPCAB) surgery. [2002.10]

Topical application of aprotinin in cardiac surgery. [2002.09]

Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study. [2002.08]

Aprotinin in coronary operation with cardiopulmonary bypass: does "low-dose" aprotinin inhibit the inflammatory response? [2002.06]

[Randomized controlled trial for the effect of amrinone and aprotinin on expression leukocyte adhesion molecule in patients with prosthetic valve replacement during perioperative period] [2002.04]

Absence of beneficial effect of acute normovolemic hemodilution combined with aprotinin on allogeneic blood transfusion requirements in cardiac surgery. [2002.02]

Cardioprotective effect of pump prime aprotinin in coronary artery bypass grafting. [2002.01]

Point-of-care testing for prothrombin time, but not activated partial thromboplastin time, correlates with laboratory methods in patients receiving aprotinin or epsilon-aminocaproic acid while undergoing cardiac surgery. [2002.01]

Aprotinin reduces postoperative bleeding and the need for blood products in thoracic surgery: results of a randomized double-blind study. [2001.12]

The effects of aprotinin and steroids on generation of cytokines during coronary artery surgery. [2001.10]

Aprotinin in orthotopic liver transplantation: evidence for a prohemostatic, but not a prothrombotic, effect. [2001.10]

Aprotinin reduces blood loss and the need for transfusion in orthognathic surgery. [2001.10]

Aprotinin but not epsilon-aminocaproic acid decreases interleukin-10 after cardiac surgery with extracorporeal circulation: randomized, double-blind, placebo-controlled study in patients receiving aprotinin and epsilon-aminocaproic acid. [2001.09.18]

Aprotinin reduces red blood cell transfusion in orthotopic liver transplantation: a prospective, randomized, double-blind study. [2001.09]

Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial. [2001.09]

Postoperatively administered aprotinin or epsilon aminocaproic acid after cardiopulmonary bypass has limited benefit. [2001.08]

Aprotinin reduces the IL-8 after coronary artery bypass grafting. [2001.08]

Reduced blood loss by aprotinin in thoracic surgical operations associated with high risk of bleeding. A placebo-controlled, randomized phase IV study. [2001.07]

[Randomized controlled trial for the effect of amrinone and aprotinin on proinflammatory cytokine release in patients with prosthetic valve replacement during perioperative period] [2001.06]

Comparison of the effects of a cell saver and low-dose aprotinin on blood loss and homologous blood usage in patients undergoing valve surgery. [2001.06]

Reduced need for vasopressors in patients receiving aprotinin during orthotopic liver transplantation. [2001.03]

Leukodepletion and aprotinin improve clinical outcome after extracorporeal circulation. [2001.03]

Low-dose aprotinin in heart valve reoperations. [2001.03]

Comparison of epsilon aminocaproic acid and low-dose aprotinin in cardiopulmonary bypass: efficiency, safety and cost. [2001.03]

Regional hemostatic status and blood requirements after total knee arthroplasty with and without tranexamic acid or aprotinin. [2001.03]

Pump prime aprotinin fails to limit proinflammatory cytokine release after coronary artery bypass surgery. [2001.02]

The effect of aprotinin on renal function in orthotopic liver transplantation. [2001.01.27]

Ultra-low dose aprotinin decreases transfusion requirements and is cost effective in coronary operations. [2001.01]

[Aprotinin (Antilysin Spofa)--its effect on decreasing hemorrhage in the postoperative period in hip arthroplasty] [2001]

High-dose aprotinin modulates the balance between proinflammatory and anti-inflammatory responses during coronary artery bypass graft surgery. [2000.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014